Comparative Pharmacology
Head-to-head clinical analysis: TECZEM versus TEKAMLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECZEM versus TEKAMLO.
TECZEM vs TEKAMLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.
Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.
One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours for diltiazem; clinical context: requires twice-daily dosing due to short half-life.
Amlodipine terminal half-life: 30-50 hours (mean 35 hours), allowing once-daily dosing; steady-state achieved after 7-8 days. Valsartan terminal half-life: ~6 hours, but pharmacodynamic effect persists due to tight AT1 receptor binding.
Renal: 40-50% unchanged; hepatic/biliary/fecal: 50-60% as metabolites.
TEKAMLO (amlodipine/valsartan) excretion: amlodipine is extensively metabolized in the liver with 60% of metabolites excreted renally and 20-25% via feces; unchanged drug in urine <10%. Valsartan is primarily excreted unchanged in feces (70-80%) via biliary elimination, and 13% in urine as unchanged drug.
Category C
Category C
Antihypertensive combination
Antihypertensive combination